全文获取类型
收费全文 | 109901篇 |
免费 | 6802篇 |
国内免费 | 314篇 |
专业分类
耳鼻咽喉 | 1366篇 |
儿科学 | 3939篇 |
妇产科学 | 2570篇 |
基础医学 | 13346篇 |
口腔科学 | 4668篇 |
临床医学 | 9577篇 |
内科学 | 23666篇 |
皮肤病学 | 2710篇 |
神经病学 | 10124篇 |
特种医学 | 3249篇 |
外国民族医学 | 1篇 |
外科学 | 16097篇 |
综合类 | 945篇 |
一般理论 | 84篇 |
预防医学 | 8404篇 |
眼科学 | 2761篇 |
药学 | 7620篇 |
中国医学 | 432篇 |
肿瘤学 | 5458篇 |
出版年
2023年 | 699篇 |
2022年 | 506篇 |
2021年 | 2488篇 |
2020年 | 1481篇 |
2019年 | 2340篇 |
2018年 | 3281篇 |
2017年 | 2304篇 |
2016年 | 2439篇 |
2015年 | 2636篇 |
2014年 | 3463篇 |
2013年 | 5036篇 |
2012年 | 7839篇 |
2011年 | 8675篇 |
2010年 | 4455篇 |
2009年 | 3490篇 |
2008年 | 7302篇 |
2007年 | 7703篇 |
2006年 | 7397篇 |
2005年 | 7328篇 |
2004年 | 6956篇 |
2003年 | 6320篇 |
2002年 | 6091篇 |
2001年 | 1896篇 |
2000年 | 1886篇 |
1999年 | 1500篇 |
1998年 | 1006篇 |
1997年 | 749篇 |
1996年 | 673篇 |
1995年 | 585篇 |
1994年 | 509篇 |
1993年 | 471篇 |
1992年 | 547篇 |
1991年 | 491篇 |
1990年 | 461篇 |
1989年 | 408篇 |
1988年 | 386篇 |
1987年 | 327篇 |
1986年 | 325篇 |
1985年 | 318篇 |
1984年 | 407篇 |
1983年 | 345篇 |
1982年 | 373篇 |
1981年 | 341篇 |
1980年 | 339篇 |
1979年 | 235篇 |
1978年 | 213篇 |
1977年 | 202篇 |
1976年 | 158篇 |
1974年 | 160篇 |
1973年 | 144篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Milena Soares Santos Guilherme de Sousa Ribeiro Tainara Queiroz Oliveira Renan Cardoso Nery Santos Edilane Gouveia Kátia Salgado Daniele Takahashi Cleuber Fontes Leila Carvalho Campos Mitermayer Galvão Reis Albert Icksang Ko Joice Neves Reis 《International journal of infectious diseases》2009,13(4):456-461
102.
103.
104.
Alan Willmore Tim Sladden Lucy Bates Craig B Dalton 《International journal of health geographics》2006,5(1):30-14
Background
To determine patterns of childhood lead exposure in a community living near a lead and zinc smelter in North Lake Macquarie, Australia between 1991 and 2002. 相似文献105.
Francisco Sampaio Pedro Mateus Nuno Bettencourt Carla Costa Dias Luís Ad?o Lino Santos Madalena Teixeira Lino Sim?es Vasco Gama 《Revista portuguesa de cardiologia》2006,25(3):321-327
INTRODUCTION: Ischemic heart disease is a major cause of heart failure in western societies. However, the factors that may influence left ventricular function (LVF) recovery after an acute coronary syndrome (ACS) are still unclear. OBJECTIVE: To identify variables that may influence LVF evolution one year after ACS. METHODS: 104 patients hospitalized with ACS between 7/1/2001 and 12/31/2002 and with systolic dysfunction--defined as an echocardiographic ejection fraction (EF) < or = 45%--were randomly allocated to a planned coronary follow-up program (FUP) or a general cardiology clinic (GC); patients from both groups were also randomly referred to a structured cardiac rehabilitation program (CRP). EF was re-assessed at one year. We compared differences between patients who recovered left ventricular function (EF > 45%; group 1) and those who did not (group 2). RESULTS: One year after discharge, 44.2% of the patients had recovered function. There were no significant differences between the groups in gender (77.7 vs. 76.5% male), age (56 vs. 59 years), hypertension, diabetes, dyslipidemia, smoking habits or family history. A previous history of cardiovascular events was more frequent in group 2 (11.1% vs. 35.3%, p = 0.03). Cardiac catheterization was performed before discharge in 88.8% and 88.2% in groups 1 and 2 respectively (p = NS); no differences were found in coronary anatomy between the two groups. Angioplasty was performed in 54.2% in group 1 and 50% in group 2 (p = NS). There were no differences in the use of angiotensin-converting enzyme inhibitors (83.3% vs. 87.5%), beta-blockers (87.5% vs. 87.5%), nitrates (37.5% vs. 33.3%), aspirin (95.8% vs. 95.8%), statins (79.1% vs. 75%) or diuretics (20.8% vs. 45.8%). There was no significant difference in LVF recovery between patients randomized to FUP or GC (38.5% vs. 54.5%). 87.5% of patients who completed the CRP had normal EF at one year compared to 32.7% of patients not referred to the program (p = 0.009). Although EF improved in both groups, this improvement was greater in patients who completed a CRP (EF 8% vs. 5%, p = 0.003). CONCLUSION: A previous cardiovascular event and completion of a CRP were the only variables that influenced LVF recovery. Thus, enrollment in a CRP, in addition to standard therapy, could be an important therapeutic measure in patients with systolic dysfunction after ACS; our data suggest that these programs should be more widely used. 相似文献
106.
107.
Pascale Jolliet Stéphane Nion Gwena?lle Allain-Veyrac L Tilloy-Fenart Dorothée Vanuxeem Vincent Berezowski Roméo Cecchelli 《Pharmacological research》2007,56(1):11-17
PURPOSE: The objective of the current study was to determine the ability of some antiemetic compounds to cross the blood-brain barrier (BBB) and thereby to determine possible side effects of compounds for the central nervous system (CNS). METHODS: We compared the brain penetration of some antiemetic compounds using an in vitro BBB model consisting in brain capillary endothelial cells co-cultured with primary rat glial cells. RESULTS: This study clearly demonstrated that the metopimazine metabolite, metopimazine acid, has a very low brain penetration, lower than metopimazine and even less than the other antiemetic compounds tested in this study. CONCLUSIONS: The poor brain penetration of metopimazine acid, metopimazine biodisponible form, seems very likely related to the clinically observed difference in therapeutic and safety profile. 相似文献
108.
109.
E. Wieczerzak E. Jankowska S. Rodziewicz‐Motowido A. Giedo J. giewka Z. Grzonka M. Abrahamson A. Grubb D. Brmme 《Chemical biology & drug design》2005,66(Z1):1-11
Abstract: We have designed and synthesized a new series of azapeptides which act as potential inhibitors of cathepsin B and/or cathepsin K. Their structures are based upon the inhibitory sites of natural cysteine protease inhibitors, cystatins. For the synthesized azapeptides, the equilibrium constants for dissociation of inhibitor–enzyme complex, Ki, were determined. Comparison of these values indicated that all of the azainhibitors act much stronger toward cathepsin B. Z‐Arg‐Leu‐His‐Agly‐Ile‐Val‐OMe ( 7 ) proved to be approximately 500 times more potent for cathepsin B than for cathepsin K. To be able to explain the obtained experimental values we used the molecular dynamics procedures to analyze the interactions between cathepsin B and compound 7 . We also determined the structure of the most potent and selective cathepsin B azainhibitor by means of NMR studies and theoretical calculations. In this report, we describe SAR studies of azapeptide inhibitors indicating the influence of the conformational flexibility of the examined compounds on inhibition of cathepsins B and K. 相似文献
110.